91 results about "L-Pyroglutamic Acid" patented technology

The invention discloses a method for preparing tegorasone pyroglutamate, and the prepared tegorasone pyroglutamate product has the advantages of reduced residual solvent content, good stability, and facilitation of the improvement of the product quality and the guarantee of the medication safety. The preparation method is simple and rapid in preparation process, beneficial to saving of production cost and suitable for industrial production.

The invention relates to the technical field of plant cultivation, and discloses a method for improving low-temperature and low-oxygen composite stress resistance of tobacco seedlings by exogenous amino acids, which comprises the following steps: selecting tobacco seedlings in a two-leaf and one-core stage of floating seedling raising; preparing an L-pyroglutamic acid mother solution; performing exogenous treatment on the selected tobacco seedlings in the two-leaf and one-core stage by using the prepared L-pyroglutamic acid mother liquor; after treatment is completed under the low-temperature and low-oxygen condition for 3 days, taking a picture of a tobacco seedling, recording phenotype, sampling roots, and measuring root length and root activity; according to measured values under the treatment of adding different volumes of L-pyroglutamic acid mother liquor with the concentration of 1g / L, data is sorted by software, difference significance analysis is carried out by data processing software, and comprehensive evaluation is carried out by a multi-character fuzzy membership function method. The application comprehensively evaluates the effect of the L-pyroglutamic acid in improving the low-temperature and low-oxygen stress resistance of the tobacco seedlings, and provides important theoretical basis and practical guidance for improving the crop stress resistance in agricultural production.

The invention belongs to the field of medicines, and discloses application of pyroglutamic acid in preparation of products for inhibiting fat deposition. The invention has the following advantages: 1, obesity induced by high fat diet is prevented; 2, pyroglutamic acid is a natural amino acid derivative, widely exists in animal and plant bodies, and has good biological safety; meanwhile, the invention further discloses a product for inhibiting fat deposition.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.

The invention provides application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract, and belongs to the technical field of medicines. The invention discloses application of D-pyroglutamic acid in preparation of a medicine for preventing and / or treating cataract. Results of the invention show that the D-pyroglutamic acid can effectively inhibit aggregation of crystalline lens proteins. In addition, the D-pyroglutamic acid drug is low in cytotoxicity, directly acts on crystalline epithelial cells and can effectively inhibit damage to the crystalline epithelial cells. Therefore, the medical application of the D-pyroglutamic acid is expanded, and meanwhile, a new diagnosis and treatment strategy is provided for attack and prevention of cataract.

The invention discloses a metabolic marker composition for early diagnosis of cervical cancer as well as a screening method and application of the metabolic marker composition. The metabolic marker composition for early diagnosis of cervical cancer comprises pyroglutamic acid, lysophosphatidylcholine 20: 3, phosphatidylcholine 32: 2 and pyruvic acid. The metabolic marker composition provided by the invention has relatively high sensitivity and specificity when being used for early-stage cervical cancer diagnosis, can realize accurate screening of early-stage cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, when the metabolic marker composition is used for early-stage cervical cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, invasion is avoided, a patient can receive detection more conveniently, rapidly and safely, and the metabolic marker composition is more suitable for large-scale population screening and regular tracking in areas with shortage of medical resources.

The invention provides a diagnostic marker for metabolic syndrome and preclinical stage thereof, and the diagnostic marker or a plasma small molecule metabolism biomarker consists of the following substances: pyrimidine, (S)-beta-aminoisobutyric acid, 3-hydroxybutyric acid, L-serine, guanidine acetic acid, 3-hydroxyisovaleric acid, L-homoserine, L-cysteine, piperidine acid, hypotaurine and creatinine. The beverage is prepared from phenylacetic acid, erythritol, picolinic acid, taurine, pyroglutamic acid, lemonic acid, malic acid, tyramine, isonicotinic acid, o-phosphoethanolamine, L-glutamine, salicylic acid and D-glucose. The invention also provides a kit for detecting the plasma small molecule metabolism biomarker composition, the spectrum peak intensity of the obtained plasma small molecule metabolism biomarker is detected, the risk score of whether each subject is MetS or pre-MetS is calculated, and then whether the subject is MetS or pre-MetS is predicted. According to the invention, efficient and rapid diagnosis of the metabolic syndrome and the preclinical stage thereof is realized.

The invention relates to the technical field of medicines, in particular to application of L-pyroglutamic acid and related products. It is found for the first time that L-pyroglutamic acid can be applied to preparation of the medicine for preventing or treating hypertension or heart and vasculopathy caused by hypertension, the treatment effect is good, safety is achieved, and a new treatment approach is provided for treating hypertension or hypertension-related diseases.

To provide a technique for reducing undesirable sourness generated during long-term storage in a food composition containing acetic acid.SOLUTION: Provided is a food composition that fulfills the following requirements (i) and (ii): (i) the content of acetic acid is 2 mass% or more; (ii) the proportion of the content (mass ppm) of pyroglutamic acid to the content (mass%) of acetic acid is 70 or less.SELECTED DRAWING: None

The application discloses derivatives of pyroglutamic acid-tetrapeptide-7 and application thereof. The derivatives of pyroglutamic acid-tetrapeptide-7 or pharmaceutically acceptable salts thereof have the following structure: the substituent R is selected from the group consisting of. The derivatives of pyroglutamic acid-tetrapeptide-7 have excellent effects of anti-inflammation, promoting synthesis of collagen and / or elastin, reducing wrinkle area or wrinkle degree, and have a smaller effective concentration compared with tetrapeptide-7, and can be applied to medicines, cosmetics or skin care products as main active ingredients.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to clofazimine-organic acid co-crystals, a preparation method and application thereof. The clofazimine-organic acid co-crystal is one of clofazimine-ferulic acid monohydrate co-crystal, clofazimine-ferulic acid co-crystal, clofazimine-glutaric acid co-crystal, clofazimine-glycolic acid co-crystal (CFZ-GA 1:1), clofazimine-glycolic acid co-crystal (CFZ-GA 1:1.5), clofazimine-salicylic acid co-crystal, clofazimine-L-aspartic acid co-crystal, clofazimine-L-pyroglutamic acid co-crystal, clofazimine-gallic acid co-crystal, clofazimine-succinic acid co-crystal, clofazimine-tartaric acid co-crystal and clofazimine-DL-mandelic acid co-crystal. The clofazimine-organic acid co-crystal provided by the application significantly improves the solubility and fluidity of clofazimine, thereby improving the bioavailability of clofazimine, and has a broad medicinal prospect.

The invention belongs to the technical field of medicines, and discloses an arbutin amino acid derivative as well as a preparation method and application thereof. According to the invention, a microbial conversion technology is utilized, the arbutin is taken as a substrate, pyroglutamic acid is introduced to the 28 site of the arbutin in a regioselective manner, and the arbutin-28beta-pyroglutamate with a novel structure is obtained. An in-vitro anti-tumor cell test proves that the compound has remarkable anti-tumor activity and can be used as an active component of an anti-tumor drug. A mouse in-vivo experiment proves that the compound has a remarkable anti-osteoporosis effect, can be used as an active ingredient of an anti-osteoporosis medicine, and has wide application.

The invention belongs to the technical field of compound preparation, and particularly provides a preparation method of L-glutamic acid-1-tert-butyl ester, which comprises the following steps: step S1, carrying out imidization reaction on an L-glutamic acid-5-methyl ester compound and benzophenone imine to generate N-dibenzylidene-L-glutamic acid-5-methyl ester; step S2, enabling the N-dibenzylidene-L-glutamic acid-5-methyl ester and tertiary butyl-2, 2, 2-trichloroacetic acid imine ester to be subjected to a tert-butyl esterification reaction, so as to generate N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester, and enabling the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester to be subjected to a tert-butyl esterification reaction; and S3, carrying out hydrolysis reaction on the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester to remove a methyl ester group, and removing a protecting group on an amino group, so as to generate the L-glutamic acid-1-tert-butyl ester. The preparation method disclosed by the embodiment of the invention is used for preparing the L-glutamic acid-5-methyl ester-1-tert-butyl ester from the N-dibenzylidene-L-glutamic acid-5-methyl ester-1-tert-butyl ester. According to the application, the tertiary butyl-2, 2, 2-trichloroacetic acid imine ester is used for carrying out the tert-butyl esterification reaction, so that the yield is high, the reaction condition is mild, the post-treatment is simple, the control on the generation of glutamic acid, pyroglutamic acid and pyroglutamic acid tert-butyl ester is facilitated, and the impurities are few.

The invention discloses an application of pyroglutamic acid butyl ester in preparation of an anti-Alzheimer disease drug, and experiments prove that the pyroglutamic acid butyl ester has a remarkable improvement effect on memory and space exploration capability of an Alzheimer disease model mouse caused by A beta 25-35, and can enhance the activity of choline acetyltransferase in cortex and hippocampus; meanwhile, the traditional Chinese medicine composition also has a remarkable improvement effect on the memory and space exploration capability of model rats with Alzheimer's disease caused by D-galactose and AlCl3, and can enhance the activity of SOD enzyme and relieve the damage of free radicals to brain tissues. Therefore, the pyroglutamic acid butyl ester has a remarkable anti-Alzheimer disease effect, can be applied to preparation of the anti-Alzheimer disease medicine, and has a good market prospect in development of clinical anti-Alzheimer disease medicines.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a metabolic marker in preparation of a product for diagnosing abdominal aortic aneurysm. The metabolic marker comprises one or more than two of 5-delta-hydroxybutyl hydantoin, I-alpha-amino acid, PGF2 alpha, D-pyroglutamic acid, nicotine glucuronide, cysteine glutathione disulfide or Trp-P-1. Experiments prove that the metabolic marker has the advantages that the metabolic marker can be applied to the field of biomarkers, and the metabolic marker can be applied to the field of biomarkers; the seven metabolites are independently or jointly used as metabolic markers for diagnosing the abdominal aortic aneurysm and have good specificity and sensitivity.

The L-theanine composition provided by the invention is placed at 60 DEG C for 10 days, the growth rate of pyroglutamic acid impurities is within 3 times, and the quality requirement that the content of the pyroglutamic acid impurities is below 1% is met; the L-theanine composition is prepared from L-theanine, an excipient and magnesium stearate, wherein the mass ratio of the L-theanine is 5%-30%; the excipient comprises one or more of pregelatinized starch, lactose, microcrystalline cellulose, mannitol, colloidal silicon dioxide and / or a pH regulator, and the mass ratio of the excipient is 65%-94.9%; the mass ratio of the magnesium stearate is 0.1%-5%. Therefore, the medicine is endowed with higher stability, so that the L-theanine preparation composition which is good in stability, effectiveness and safety and meets the pharmacopoeia standard is obtained. Meanwhile, related pharmacodynamic experiments are carried out by the inventor, and it is proved that the composition can be used for preparing the medicine for preventing and / or treating vaginitis.

LSD derivative compounds and polymorphs thereof, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula I' selected from,,,, or combination thereof, wherein the acid is selected from formic acid, malic acid (D and L), pyroglutamic acid (D and L), citric acid, phosphoric acid, aspartic acid (D and L), methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, sulfuric acid, glutamic acid (D and L), ascorbic acid (D and L), isoascorbic acid (D and L), hydrochloric acid, hydrobromic acid, ethane sulfonic acid, tartaric acid (D and L), or meso-tartaric acid.

The invention discloses a method for detecting L-pyroglutamic acid and methionine sulfoxide in a compound amino acid injection, and relates to the technical field of medicine detection.Chromatographic conditions of a high performance liquid chromatography are as follows: gradient elution is performed by adopting a chromatographic column of an octadecylsilane chemically bonded silica filler and a mobile phase consisting of a mobile phase A and a mobile phase B, a detector is an ultraviolet detector, the detection wavelength is 205-210 nm, the flow velocity of a mobile phase is 0.7-1.2 ml / min, the sample size is 5-25 [mu] l, the column temperature is 20-25 DEG C, the mobile phase A is a mixed solution of an ion pair reagent, a phosphate buffer solution, methanol and acetonitrile, and the mobile phase B is one or more of a methanol solution, an acetonitrile solution and a phosphate buffer solution; the detection process comprises the following steps: injecting a test solution into a liquid chromatograph, recording a chromatogram, and calculating the contents of methionine sulfoxide and L-pyroglutamic acid by peak areas according to an external standard method.

The invention discloses application of pyroglutamic acid butyl ester in preparation of antihypertensive drugs, experiments prove that the pyroglutamic acid butyl ester has a remarkable antihypertensive effect on spontaneously hypertensive rats, and the effect of the pyroglutamic acid butyl ester is obviously superior to that of a positive control drug olmesartan medoxomil; particularly, along with the prolonging of the treatment time, the advantage of the antihypertensive effect is more obvious than that of olmesartan medoxomil; and meanwhile, the safety is good. Therefore, the pyroglutamic acid butyl ester has a remarkable antihypertensive effect, can be applied to preparation of antihypertensive drugs, and has a good market prospect in development of clinical antihypertensive drugs.

The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

To provide a technology for suppressing unpleasant sourness that occurs in a food composition containing acetic acid when stored for a long period of time. [Solution] A food composition that satisfies the following requirements (i) and (ii). (i) The acetic acid content is 3.0% by mass or more. (ii) The ratio of the pyroglutamic acid content (ppm by mass) to the acetic acid content (% by mass) is 70 or less.

To provide a new alcoholic beverage having various flavor attributes favorable for use as an alcoholic beverage.SOLUTION: An alcoholic beverage containing 10.0 to 180.0 mg / L of pyroglutamic acid, 12.0 to 55.0 mg / L of ethyl acetate, and a total of 130.0 to 900.0 μg / L of ethyl hexanoate and ethyl octanoate.SELECTED DRAWING: None

To meet a need for a fermented beverage that is made by using hops and offers a favorable, characteristic flavor typical of a fermented beverage while achieving a reduction in unsuitable grain odor.SOLUTION: Provided is a fermented beverage that is made by using hops as a raw material, has a pyroglutamic acid content of 95.0 mg / L or less, and satisfies formula (1): A / B≤30.0, wherein in formula (1), A represents the pyroglutamic acid content (unit: mg / L) and B represents the free amino nitrogen content (unit: mg / 100 mL).SELECTED DRAWING: None

An antibody or antigen-binding fragment thereof that binds to A [beta] pE3, i.e., to the N-terminal truncated and pyroglutamic acid modified form of amyloid [beta] (A [beta]), and therapeutic and diagnostic uses thereof are disclosed.

The processed food product has a xanthine / pyroglutamic acid ratio between the xanthine content (units: μg / g) and the pyroglutamic acid content (units: μg / g) of 0.0200 or less and a pyroglutamic acid content of 40 μg / g or greater. The processed food contains at least one component (X) selected from the group consisting of a protein having had xanthine oxidase activity and a component derived from the protein.

The application provides a pyroglutamic acid transaminase mutant and application thereof, the mutant is obtained by mutation on the basis of wild-type pyroglutamic acid transaminase, and specific mutation includes at least one of the following sites: (1) the 13th isoleucine is mutated into arginine; (2) the 35th valine is mutated into arginine; (3) the 183rd asparagine is mutated into aspartic acid; and the mutant is suitable for industrial enzymatic production of L-aspartic acid and the process of amino acids taking L-aspartic acid as a precursor; especially, the I13R / V35R / N183D mutant obtained by modification has high positive catalytic activity and strict direction selectivity, and completely loses the reverse reaction activity of decomposing L-aspartic acid; the mutant is overexpressed with phosphoenolpyruvate carboxylase in L-threonine production strain THRS-6, and a high-efficiency L-threonine synthesis metabolic pathway is constructed, and the yield of L-threonine is significantly improved when glucose is used as a substrate.

The invention relates to the field of medicinal chemistry, in particular to a preparation method of L-pyroglutamic acid etogliflozin. An ethyl acetate / water system is adopted to dissolve an L-pyroglutamic acid etogliflozin crude product, after filtration, n-heptane is added, cooling and crystallization are performed to obtain the L-pyroglutamic acid etogliflozin, in the prepared product, the ratio of the etogliflozin to the L-pyroglutamic acid eutectic crystal is stable, the residual amount of a solvent is low, the content of an impurity Y can be controlled to be 0.05% or below, the minimum content can be controlled to be 0.02%, the product purity is high, and the yield is high. The yield is high. The method is low in production cost, simple to operate, high in yield, high in product purity, stable in quality and suitable for industrial production.

The application belongs to the technical field of food preparation, and particularly relates to application of pyroglutamic acid in fresh-cut fruit and vegetable preservation, browning resistance and bacterium inhibition. Fresh-cut fruit and vegetable are treated by the method, so that the browning degree of fresh-cut potato, lettuce, lotus root slice and other products during a shelf life is significantly delayed, the growth of microorganisms during the shelf life of the products is reduced, and the shelf life is prolonged. The anti-browning and bacterium-inhibiting preservative for fresh-cut fruit and vegetable provided by the application is safe, efficient and environmentally friendly.

Cosmetic or dermatological composition comprising at least a merocyanine and a hydrotrope The present invention relates to a cosmetic or dermatological composition comprising an aqueous phase, and a merocyanine of formula (I):and at least one hydrotrope chosen from nicotinamide, caffeine, salicylic acid salts, the sodium salt of pyroglutamic acid (sodium PCA), sodium 1,3-benzenedisulfonate, sodium benzoate, sodium 4-pyridinecarboxylate, sodium benzenesulfonate, sodium p-toluenesulfonate (NaPTS), sodium butyl monoglycol sulfate (NaBMGS), 4-aminobenzoic acid HCl, sodium cumene sulfonate, N,N-diethyl nicotinamide, N-picolyl nicotinamide, N-allyl nicotinamide, 2-methacryloyloxyethyl phosphorylcholine, resorcinol, pyrogallol, N-picolylacetamide, procaine HCl, proline HCl, pyridine, 3-picolylamine, sodium ibuprofen, sodium xylene sulfonate (SXS), ethyl carbamate, pyridoxal hydrochloride, sodium benzoate, N,N-dimethylacetamide, N-methylacetamide, isoniazid, and mixtures thereof.